Funding for this research was provided by:
University of Gothenburg
Received: 10 March 2021
Accepted: 11 October 2021
First Online: 10 January 2022
Change Date: 28 January 2022
Change Type: Update
Change Details: The family name of author Roger Olofsson Bagge has been corrected.
: The study was approved by the Swedish Ethical Review Authority (reference number 995–16) and written informed consent was obtained from all patients.
: Not applicable.
: R. C. and C.L. have developed EV-associated patents for putative clinical utilization. R.C. and C.L. own equity in Exocure Bioscience Inc. ROB has received institutional research grants from Astra Zeneca, Bristol-Myers Squibb (BMS) and SkyLineDx, speaker honorarium from Roche and Pfizer and has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche and Sanofi Genzyme. K. E. holds assets in Codiak BioSciences, Inc. Remaining authors have no competing interest.